Want to see NNVC full AI Analyst Report?
NNVC Stock Chart & Stats
$1.48
$0.06(4.05%)
At close: 4:00 PM EDT
$1.48
$0.06(4.05%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous Close$1.56
Volume474.58K
Average Volume (3M)143.34K
Market Cap
$38.61M
Enterprise Value$20.73M
Total Cash (Recent Filing)$3.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding25,399,155
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-159.92
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$6.00Price Target Upside305.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero reported debt materially reduces financial risk and preserves balance sheet flexibility. For a pre-commercial biotech this lowers bankruptcy risk, eases covenant pressure, and gives management optionality to prioritize R&D or seek non-debt financing over the medium term.
Proprietary Antiviral Platform & ManufacturingA platform approach targeting multiple viruses creates potential for pipeline breadth and repeatable drug design. Combined with in-house manufacturing, the company can control clinical supply timelines and costs, accelerating development and reducing reliance on external CDMOs long-term.
Established Access To Equity CapitalDemonstrated ability to raise capital through registered directs and an ATM provides recurring funding channels to support ongoing trials and R&D. Structural access to equity markets improves runway management and enables program continuity absent near-term product revenue.
Bears Say
No Revenue / Persistent LossesA pre-commercial revenue profile with multi-year net losses means the company must convert clinical programs into approved products to achieve sustainability. Until then, operating deficits erode equity and require ongoing external capital, increasing long-term execution risk.
Negative Operating And Free Cash FlowConsistent annual free cash flow burn (~$6–9M historically) plus a materially larger TTM outflow compresses runway and elevates financing dependency. Structural negative FCF weakens self-funding prospects and forces dilution or strategic trade-offs if trials cost more than planned.
Equity Dilution / Equity Base ErosionRepeated reliance on equity raises and an ATM program, together with reported equity declines since 2021, implies structural dilution risk. Ongoing issuance to fund operations can erode shareholder value and pressure governance choices until commercial revenue offsets financing needs.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $38.61M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 110 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Undervalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 25,399,155 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NanoViricides Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (305.41% Upside)
$6.00 (305.41% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.86%
Trailing 12-Months
Company Description
NanoViricides
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
NNVC Stock 12 Month Forecast
Average Price Target
$6.00
▲(305.41% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.71% Mutual Funds
0.64% Other Institutional Investors
92.97% Public Companies and
Individual Investors